Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
about
Targeted therapy for HER2 positive breast cancerErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.FoxM1 is a downstream target and marker of HER2 overexpression in breast cancerTargeting the tumor microenvironment: focus on angiogenesis.HER2-directed therapy: current treatment options for HER2-positive breast cancer.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.ErbB3 is required for ductal morphogenesis in the mouse mammary gland.ErbB receptors in the biology and pathology of the aerodigestive tractEGFR family: structure physiology signalling and therapeutic targets.Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaEmerging molecular targeted therapies in the treatment of head and neck cancer.Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancerErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases.Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.Biomarkers of drugs targeting HER-family signalling in cancer.Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.Kinase inhibitors of HER2/AKT pathway induce ERK phosphorylation via a FOXO-dependent feedback loopNanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry.Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy.Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells.
P2860
Q26830496-32246960-DF3B-4A2B-943D-484F46B54BE8Q30457869-3ABEA5FA-1EAF-44B3-840B-1BCF1D86C2EDQ30474678-887D8ACF-8712-41D9-94D4-97B939512F8DQ32884377-4ED029F1-817D-43BE-BF44-BA8888FEF5CAQ33354783-5B0E6C37-927A-4558-8C8E-06950903B4FDQ33709971-1696079E-8F96-4B23-A416-1F1109C1FBD6Q33740638-25D36892-BA47-4DBF-9E90-4CD3BE5F26DEQ34725700-1B9ACC7C-88FD-4B56-A782-886E7BB278BFQ35184806-40CCE290-A891-438E-9E9F-CD2C7775462CQ35551522-390B8F10-7A7A-48D4-A3D7-BF3219CAAF56Q35624814-021858A2-D355-450B-BD76-EE1F96F92C1DQ37121790-287FC919-6ACD-4773-9387-7EFC259BC2F4Q37131318-AFFB4DEF-0D66-45E5-821B-923F29F619FDQ37263452-24FF4A47-7063-4A1A-BC94-2545386533F0Q37272623-F0AFB061-4F0B-43BD-B8F2-7C1E8AD2CFB1Q37317395-2C6A7909-5A8F-40F9-A1CB-A897FF404576Q37351498-D3B5F6B2-6928-40AF-8F7B-B1EBC9C6E3D5Q37515438-D34F880F-E821-40FA-8B6B-AA26990ED64DQ37636623-2F9814EE-B696-4E16-87DD-34C736E55073Q37668848-5C80DDFA-93C9-4354-8322-B03990AD6F90Q37826199-65BE2354-58F5-448D-AB63-0ED87DFB6631Q38044021-8C05F86E-0F70-461A-AFE6-44F6BF978BBCQ38150774-B0B73798-F990-44F4-9830-F19F83910639Q38728508-01B50995-D945-4945-B6AF-5F16E8E07165Q38841033-8EA8875C-710A-4197-AB8F-E6363BDCB342Q39251000-497BE207-A9E9-4B1F-94F2-5A518939F727Q39312902-7EA27EAC-52E3-4F7E-B02E-B03B6D133898Q39620638-E240965C-4904-4FEF-A302-2E15DEFF9E7CQ41098249-F6C43230-B327-4CC7-9BAA-496F8BAA475FQ42366735-FB022341-137E-494D-872C-A3972089C3BDQ42416926-A11769D9-8A64-4109-860B-285513D816CFQ42706133-06B6BCF0-57EC-4383-BDA3-9C2F4B5C3153
P2860
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
@ast
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
@en
type
label
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
@ast
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
@en
prefLabel
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
@ast
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
@en
P2093
P2860
P356
P1476
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
@en
P2093
Filippo Montemurro
Giorgio Valabrega
Massimo Aglietta
P2860
P304
P356
10.1517/14712598.7.2.257
P407
P577
2007-02-01T00:00:00Z